Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma.
Adriamycin (50 mg/m2) and cis-diamminedichloroplatinum (50 mg/m2) were administered every 21 days to treat metastatic endometrial adenocarcinoma. This regimen resulted in three responses (one complete and two partial) in nine women (33%). Most patients had moderate or severe hematologic and gastrointestinal toxicity. One patient experienced moderate neurotoxicity. This combination of drugs did not appear effective in the treatment of recurrent endometrial adenocarcinoma, but may have a role in the therapy of primary widespread disease.